Rigel Pharmaceuticals names new Chief Medical Officer By Investing.com
[ad_1]
© Reuters.
SOUTH SAN FRANCISCO, Calif. – Rigel (NASDAQ:) Pharmaceuticals, Inc. (NASDAQ:RIGL) has announced the appointment of Lisa Rojkjaer, M.D., as its new Executive Vice President and Chief Medical Officer today. Dr. Rojkjaer, a board-certified hematologist, brings over two decades of experience in clinical development, regulatory affairs, and medical affairs, with a specialization in hematology and oncology.
Rigel’s President and CEO, Raul Rodriguez, expressed confidence in Dr. Rojkjaer’s appointment, highlighting her industry leadership and expertise in drug development as valuable assets to Rigel’s leadership team. Her role is expected to support the company’s clinical portfolio growth, particularly in light of recent collaborations aimed at expanding the evaluation of olutasidenib in IDH1-mutant cancers and the ongoing Phase 1b trial of R289 for lower-risk myeloid dysplastic syndrome (LR-MDS).
Dr. Rojkjaer’s previous experience includes serving as Chief Medical Officer at Sangamo Therapeutics, as well as leadership roles at Viracta Therapeutics, Nordic Nanovector, and Novartis (SIX:) Pharmaceuticals. At Novartis, she led the development and regulatory approval of Rydapt®, a treatment for FLT3 mutation-positive acute myeloid leukemia (AML). Her career has also spanned positions at Molecular Partners, MorphoSys AG, and Novo Nordisk (NYSE:).
The new CMO expressed enthusiasm about joining Rigel during a pivotal time as the company’s hematology and oncology portfolio gains momentum. Dr. Rojkjaer’s appointment is part of Rigel’s broader efforts to advance therapies for patients with significant unmet medical needs.
Rigel Pharmaceuticals , founded in 1996 and headquartered in South San Francisco, focuses on developing therapies for hematologic disorders and cancer. The company’s forward-looking statements in the press release indicate ongoing efforts to progress clinical stage programs and commercialize products, despite acknowledging the inherent risks and uncertainties in drug development and commercialization.
The press release also contains forward-looking statements regarding Rigel’s future endeavors, including clinical trials and product commercialization. These statements are based on current expectations and involve risks and uncertainties, including those outlined in Rigel’s filings with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
© Reuters.
SOUTH SAN FRANCISCO, Calif. – Rigel (NASDAQ:) Pharmaceuticals, Inc. (NASDAQ:RIGL) has announced the appointment of Lisa Rojkjaer, M.D., as its new Executive Vice President and Chief Medical Officer today. Dr. Rojkjaer, a board-certified hematologist, brings over two decades of experience in clinical development, regulatory affairs, and medical affairs, with a specialization in hematology and oncology.
Rigel’s President and CEO, Raul Rodriguez, expressed confidence in Dr. Rojkjaer’s appointment, highlighting her industry leadership and expertise in drug development as valuable assets to Rigel’s leadership team. Her role is expected to support the company’s clinical portfolio growth, particularly in light of recent collaborations aimed at expanding the evaluation of olutasidenib in IDH1-mutant cancers and the ongoing Phase 1b trial of R289 for lower-risk myeloid dysplastic syndrome (LR-MDS).
Dr. Rojkjaer’s previous experience includes serving as Chief Medical Officer at Sangamo Therapeutics, as well as leadership roles at Viracta Therapeutics, Nordic Nanovector, and Novartis (SIX:) Pharmaceuticals. At Novartis, she led the development and regulatory approval of Rydapt®, a treatment for FLT3 mutation-positive acute myeloid leukemia (AML). Her career has also spanned positions at Molecular Partners, MorphoSys AG, and Novo Nordisk (NYSE:).
The new CMO expressed enthusiasm about joining Rigel during a pivotal time as the company’s hematology and oncology portfolio gains momentum. Dr. Rojkjaer’s appointment is part of Rigel’s broader efforts to advance therapies for patients with significant unmet medical needs.
Rigel Pharmaceuticals , founded in 1996 and headquartered in South San Francisco, focuses on developing therapies for hematologic disorders and cancer. The company’s forward-looking statements in the press release indicate ongoing efforts to progress clinical stage programs and commercialize products, despite acknowledging the inherent risks and uncertainties in drug development and commercialization.
The press release also contains forward-looking statements regarding Rigel’s future endeavors, including clinical trials and product commercialization. These statements are based on current expectations and involve risks and uncertainties, including those outlined in Rigel’s filings with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
About The Author
